Robinhood reports August 2025 customer and trading metrics
Investing.com - Guggenheim raised its price target on ANI Pharmaceuticals (NASDAQ:ANIP) to $114.00 from $86.00 on Monday, while maintaining a Buy rating on the stock. The company, currently valued at $1.92 billion, has seen its shares surge over 57% in the past year, trading near its 52-week high. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.
The price target increase follows ANI’s second-quarter 2025 earnings report released last month, which showed significant top and bottom-line beats driven by strong performance from Cortrophin Gel.
ANI Pharmaceuticals also announced favorable updates to its fiscal year 2025 guidance for several key metrics, including Cortrophin Gel net revenues, total company net revenues, and non-GAAP diluted earnings per share.
The company is facing market access challenges that continue to negatively impact U.S. sales of Iluvien and Yutiq, prompting a decrease in fiscal year revenue guidance for those products. However, these decreases are more than offset by the strength in Cortrophin.
Guggenheim views ANI Pharmaceuticals as uniquely positioned to deliver fundamental upside while remaining relatively immune to macro uncertainties affecting the broader biopharma segment, including potential pharma tariffs, potential changes to U.S. drug pricing, and leadership turnover at the FDA.
In other recent news, ANI Pharmaceuticals reported impressive financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted earnings per share (EPS) of $1.80, exceeding the FactSet consensus estimate of $1.41. Revenue also outperformed forecasts, reaching $211.4 million against an anticipated $187.34 million. This strong performance was largely driven by the Cortrophin Gel product, which generated $81.6 million in revenue, marking a 66% year-over-year increase. As a result, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS.
Additionally, analysts have responded positively to these developments. Truist Securities increased its price target for ANI Pharmaceuticals to $77, maintaining a Hold rating, citing the outperformance of the Cortrophin product line. H.C. Wainwright also raised its price target from $84 to $93, while maintaining a Buy rating, acknowledging the company’s significant revenue growth. These recent developments highlight the company’s strong financial health and positive outlook among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.